13.18
+0.6(+4.77%)
Currency In USD
| Previous Close | 12.58 |
| Open | 12.49 |
| Day High | 13.22 |
| Day Low | 12.49 |
| 52-Week High | 17.15 |
| 52-Week Low | 9.49 |
| Volume | 478,257 |
| Average Volume | 158,853 |
| Market Cap | 345.94M |
| PE | -12.67 |
| EPS | -1.04 |
| Moving Average 50 Days | 14.26 |
| Moving Average 200 Days | 13.56 |
| Change | 0.6 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $11.75 as of December 04, 2025 at a share price of $13.18. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $280.9 as of December 04, 2025 at a share price of $13.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
GlobeNewswire Inc.
Nov 06, 2025 5:19 AM GMT
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di
Benitec Biopharma Inc. Announces Proposed Public Offering
GlobeNewswire Inc.
Nov 05, 2025 9:43 PM GMT
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- di
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
GlobeNewswire Inc.
Nov 03, 2025 12:10 PM GMT
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designation from bot